Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or VSports app下载. mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely V体育官网. .

. 2010 Feb;138(2):583-94.
doi: 10.1053/j.gastro.2009.10.037. Epub 2009 Oct 29.

Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice

Edwin F de Zoeten  1 , Liqing Wang, Hong Sai, Wolfgang H Dillmann, Wayne W Hancock
Affiliations

Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice

"V体育平台登录" Edwin F de Zoeten et al. Gastroenterology. 2010 Feb.

Abstract

Background & aims: Foxp3+ T regulatory cells (Tregs) help prevent autoimmunity, and increases in their numbers of functions could decrease the development of inflammatory bowel disease. Like other cells, Foxp3+ Tregs express histone/protein deacetylases (HDACs), which regulate chromatin remodeling and gene expression VSports手机版. We investigated whether disruption of a specific class IIa HDAC, HDAC9, activity in Tregs affects the pathogenesis of colitis in mice. .

Methods: We tested the effects of various HDAC inhibitors (HDACi) in models of colitis using wild-type mice. We also transferred Tregs and non-Treg cells from HDAC9-/- or wild-type mice to immunodeficient mice V体育安卓版. HDAC9 contributions to the functions of Tregs were determined during development and progression of colitis. .

Results: Pan-HDACi, but not class I-specific HDACi, increased the functions of Foxp3+ Tregs, prevented colitis, and reduced established colitis in mice, indicating the role of class II HDACs in controlling Treg function. The abilities of pan-HDACi to prevent/reduce colitis were associated with increased numbers of Foxp3+ Tregs and their suppressive functions. Colitis was associated with increased local expression of HDAC9; HDAC9-/- mice resistant to development of colitis. HDAC9-/- Tregs expressed increased levels of the heat shock protein (HSP) 70, compared with controls. Immunoprecipitation experiments indicated an interaction between HSP70 and Foxp3 V体育ios版. Inhibition of HSP70 reduced the suppressive functions of HDAC9-/- Tregs; Tregs that overexpressed HSP70 had increased suppressive functions. .

Conclusions: Strategies to decrease HDAC9 expression or function in Tregs or to increase expression of HSP70 might be used to treat colitis and other autoimmune disorders. VSports最新版本.

PubMed Disclaimer

V体育官网 - Conflict of interest statement

Conflicts of interest

The authors disclose no conflicts.

Figures

Figure 1
Figure 1
Contrasting effects of pan-HDACi and class I-specific HDACi therapy on colitis. Mice (n = 10/group) receiving DSS plus TsA, SAHA, MS275, or DMSO carrier alone were evaluated daily for (A) weight loss (mean ± SD), (B) bleeding, and (C) stool consistency. Mice receiving TsA or SAHA had less weight loss, stool blood, or diarrhea (P < .01) than mice treated with MS275 or DMSO. (D) H&E-stained colonic sections (original magnification, ×125) from mice receiving DSS and treatment for 10 days with TsA dissolved in DMSO or DMSO alone (representative of n = 6/group). (E) qPCR analysis of colons from normal mice or those receiving DSS or DSS plus TsA, SAHA, or MS75 at day 10 after initiation of DSS therapy; data (mean ± SD, n = 6/group) are expressed as fold increase compared with levels in normal WT colons and were normalized to 18S; Foxp3, P < .01 for TsA or SAHA vs DMSO or MS275; IL-10, P < .05 for TsA and P < .01 for SAHA vs control or MS275; IL-2,P < .005 for TsA or SAHA vs control or MS275; IFN-γ, P < .02 for TsA or SAHA vs control or MS275; TNF-α, P < .01 for TsA or SAHA vs control of MS275; and TGF-β, P < .05 for SAHA vs MS275; differences in TGF-β expression between DSS or TsA were not significant (P < .05). (F) Intracellular staining of lamina propria mononuclear cells on day 10 shows a decreased proportion of cells expressing TNF-α (P < .05) and an increased proportion of cells expressing IL-10 (P < .01) in mice receiving TSA or SAHA (representative of n = 6 mice/group).
Figure 2
Figure 2
Contrasting effects of pan-HDACi and class I-specific HDACi therapy on Treg function in vivo. After 7 days of in vivo therapy in normal C57BL/6 mice using MS275 or SAHA, CD4+CD25+ cells were isolated using magnetic beads and added to cultures of CFSE-labeled CD4+CD25− T cells that were activated with CD3 mAb and irradiated antigen-presenting cells. The percentage of proliferating T cells is shown in each plot, and data are representative of 3 experiments.
Figure 3
Figure 3
Pan-HDACi therapy and prevention or treatment of T cell-induced colitis. Panels A and B show prevention data, and panels C and E involve treatment once colitis had developed. (A) Rag1−/− mice (mean ± SD, n = 8/group) adoptively transferred with 1 × 106 C57BL/6 CD4+CD25− cells and treated with TsA (yellow) or SAHA (red) did not develop colitis, in contrast to mice treated with MS275 (green, P < .03) or DMSO alone (blue, P < .01). (B) Flow cytometry of mesenteric LN cells harvested at 14 days showed increased Foxp3+ Tregs in TsA-treated mice; data representative of n = 8 mice/group. (C) Rag1−/− mice (mean ± SD, n = 8/group) adoptively transferred with 1 × 106 C57BL/6 CD4+CD25− cells developed clinical evidence of colitis and >20% weight loss by ~55 days posttransfer. In contrast to use of DMSO alone (blue), mice treated with TsA (red) showed clinical improvement (P < .005). (D) Flow cytometry of mesenteric LN cells harvested at 14 days after onset of therapy showed increase in Foxp3+ Tregs in TsA-treated mice; data representative of n = 8/group. (E and F) Representative histology (n = 8/group, Alcian blue; original magnification, ×125) after 3 weeks of therapy with DMSO (E) vs TsA (F), showing differential effects on leukocyte infiltration, goblet cell loss, and submucosa thickening.
Figure 4
Figure 4
HDAC9 and colitis. (A) qPCR analysis of HDAC expression in colons of DSS-treated mice; data (mean ± SD, n = 6/group) expressed as fold increase over levels in normal colons (after normalization to 18S). (B) Rag−/− mice were injected with 1 × 106 WT CD4+CD25− naïve T cells, and weights (mean ± SD, n = 8/group) were measured at least twice weekly. Once colitis had developed, mice were injected with 5 × 105 CD4+CD25+ cells from naïve C57BL6 (red) or HDAC9−/− mice (green) or with control naïve CD4+CD25− cells (blue); **P < .005 for WT Tregs vs Teff cells and *P < .01 for HDAC9−/− vs WT Tregs. (C) Flow cytometric quantitation of splenocyte and mesenteric lymph node (MLN) cell numbers (mean ± SD, n = 4 mice/group) at 21 days after injection of CD4+CD25+ cells from HDAC9−/− vs WT Tregs (*P < .01). (D–F) Representative histology (n = 8/group) at 21 days posttransfer of indicated cell populations (Alcian blue; original magnification, ×100).
Figure 5
Figure 5
HDAC9 knockdown and Foxp3+ Treg suppression. (A) qPCR analysis (mean ± SD, n = 4/group) of effects of HDAC9 knockdown on gene expression in resting and activated in naïve CD4+CD25+ cells; data normalized relative to 18S (*P < .05 and **P < .01 vs use of control siRNA). (B) Effects of HDAC9 knockdown on Treg function in vitro; data shown as number of proliferating cells (upper panel) and as percentage proliferating cells at each ratio (lower panel); data representative of 4 experiments (*P < .05 vs corresponding control siRNA value).
Figure 6
Figure 6
Conversion of HDAC9−/− vs WT CD4+CD25− cells. (A) WT and HDAC9−/− CD4+CD25− cells were cultured for 3 days with plate-bound CD3 and CD28 mAbs, plus IL-2 (10 U/mL) and increasing concentrations of TGF-α; the percentages of CD4+Foxp3+ cells are shown and are representative of 4 experiments. (B) WT and HDAC9−/− CD4+CD45RBhi CD4+CD25− cells (1 × 106 cells) were injected IP into Rag1−/− mice; spleen, mesenteric lymph node (MLN), and peripheral lymph node (LN) samplers harvested at the weeks indicated were analyzed by flow cytometry; data representative of 4 experiments.
Figure 7
Figure 7
Pharmacologic effects of HSP70 inhibition in Tregs. (A) qPCR analysis of HSP40 and HSP70 expression by resting or activated Tregs (using CD3/CD28 mAbs) from HDAC9−/− and WT mice; data shown as fold increase, normalized relative to 18S and representative of 3 experiments. (B) Flow cytometric analysis of WT or HDAC9−/− Treg cell apoptosis as shown by Annexin-V staining. Left panel shows Annexin-V staining of the cell populations after culture for 24 hours with CD3 mAb and IL-2. Right panel shows corresponding analysis of HDAC9−/− cells cultured with or without addition of Triptolide (data representative of 3 experiments). (C) Inhibitory effects of increasing concentrations of Triptolide on the functions of HDAC9−/− Tregs in vitro using a standard Treg suppression assay involving proliferation of CFSE-labeled T cells; percentage of CFSE+ cells in each well is indicated (data representative of 3 experiments).
Figure 8
Figure 8
HSP70 and Foxp3 expression in Tregs. (A) Comparison of Treg conversion at 3 and 6 days of culture of HDAC9−/− and WT T cells in presence of CD3 mAb (1 µg/mL), TGF-β (3 ng/mL), and IL-2 (5 U/mL). (B) Comparison of proliferation of WT and HDAC9−/− CFSE-labeled Tregs cultured for 3 days with CD3 mAb and irradiated APC, with or without IL-2 (5 U/mL) as indicated. (C) Assessment of Treg proliferation under Treg assay-like conditions. CFSE-labeled CD4+CD25+ T cells and unlabeled CD4+CD25− T cells (Teff) cells were stimulated for 72 hours with CD3 mAb (0.5 µg/mL) plus 4 × 105 irradiated APC; percentage of CFSE-labeled CD4+CD25+ T cells at each ratio of Teff to Treg is indicated. (D) Immunoprecipitation of HSP70 from WT Tregs leads to coprecipitation of Foxp3 (47 kilodaltons, lowermost molecular weight marker). (E) Increased coprecipitation of HSP70 and Foxp3 using HDAC9−/− vs WT Tregs and lack of coprecipitation of HSP70 and Foxp3 when using CD4+CD25− T cells. In panels A–E, data are representative of 3 experiments.
See this image and copyright information in PMC

References

    1. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med. 2002;347:911–920. - PubMed (V体育官网)
    1. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol. 2002;20:495–549. - PubMed
    1. Singh B, Read S, Asseman C, et al. Control of intestinal inflammation by regulatory T cells. Immunol Rev. 2001;182:190–200. - PubMed
    1. Mottet C, Uhlig HH, Powrie F. Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J Immunol. 2003;170:3939–3943. - PubMed
    1. Duchmann R, Kaiser I, Hermann E, et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) Clin Exp Immunol. 1995;102:448–455. - PMC - PubMed

Publication types

MeSH terms